SEC Form 4 · accession 0001179110-17-013550
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maria Teresa Hilado
Officer — Chief Financial Officer
Period of report
Oct 26, 2017
Accepted (ET)
Oct 30, 2017 · 9:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001F1,F2,F3 | Oct 26, 2017 | M | 7,120 | — | A | 26,810 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Based Restricted Share UnitF2 | — | Oct 26, 2017 | M | 7,120 | D | — | — | Ordinary Shares | 7,120 | 0 | D |
Explanation of responses
- F1The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest in equal installments on each of December 31, 2017, December 31, 2018 and December 31, 2019.
- F2Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.
- F3Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.